| 1 |
34968705 | Mitochondrial superoxide targets energy metabolism to modulate epigenetic regulation of NRF2-mediated transcription. | 2022 Feb 1 |
2 |
| 2 |
35267433 | Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations. | 2022 Feb 22 |
1 |
| 3 |
32796956 | Identification and characterization of isocitrate dehydrogenase 1 (IDH1) as a functional target of marine natural product grincamycin B. | 2021 May |
1 |
| 4 |
33367952 | Differential expression of the BCAT isoforms between breast cancer subtypes. | 2021 May |
1 |
| 5 |
33578097 | Chronic nickel (II) exposure induces the stemness properties of cancer cells through repressing isocitrate dehydrogenase (IDH1). | 2021 Apr 15 |
2 |
| 6 |
33713004 | Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases. | 2021 Jul |
2 |
| 7 |
33808599 | The Interactome between Metabolism and Gene Mutations in Myeloid Malignancies. | 2021 Mar 19 |
1 |
| 8 |
33981605 | Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer. | 2021 |
5 |
| 9 |
34065652 | Evaluating Mechanisms of IDH1 Regulation through Site-Specific Acetylation Mimics. | 2021 May 16 |
1 |
| 10 |
34095989 | IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment. | 2021 Jul |
1 |
| 11 |
34143606 | Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate. | 2021 Jun 29 |
2 |
| 12 |
34321251 | Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies. | 2021 Oct |
2 |
| 13 |
34356864 | IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications? | 2021 Jul 10 |
2 |
| 14 |
34725432 | Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1. | 2021 Nov 1 |
3 |
| 15 |
34854890 | Isocitrate dehydrogenase gene variants in cancer and their clinical significance. | 2021 Dec 17 |
3 |
| 16 |
31485826 | To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma. | 2020 Jan |
2 |
| 17 |
31960518 | Metabolic changes related to the IDH1 mutation in gliomas preserve TCA-cycle activity: An investigation at the protein level. | 2020 Mar |
1 |
| 18 |
32150688 | Role of Isocitrate Dehydrogenase 2 on DNA Hydroxymethylation in Human Airway Smooth Muscle Cells. | 2020 Jul |
5 |
| 19 |
32313423 | Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas. | 2020 |
1 |
| 20 |
32373065 | Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism. | 2020 |
1 |
| 21 |
32705169 | Wild‑type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells. | 2020 Sep |
6 |
| 22 |
32727816 | Gene of the month: IDH1. | 2020 Oct |
2 |
| 23 |
32729927 | An acidic residue buried in the dimer interface of isocitrate dehydrogenase 1 (IDH1) helps regulate catalysis and pH sensitivity. | 2020 Aug 28 |
2 |
| 24 |
32754276 | MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma. | 2020 |
2 |
| 25 |
32777735 | Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities. | 2020 Aug |
4 |
| 26 |
32824685 | IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment-Current State and Future Perspectives. | 2020 Aug 18 |
1 |
| 27 |
32825279 | Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications. | 2020 Aug 20 |
1 |
| 28 |
32878781 | Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1). | 2020 Sep |
2 |
| 29 |
32880665 | Chiral discrimination in a mutated IDH enzymatic reaction in cancer: a computational perspective. | 2020 Oct |
2 |
| 30 |
32955829 | Enasidenib and ivosidenib in AML. | 2020 Oct |
1 |
| 31 |
30483760 | The oncometabolite d‑2‑hydroxyglutarate induces angiogenic activity through the vascular endothelial growth factor receptor 2 signaling pathway. | 2019 Feb |
1 |
| 32 |
30573870 | Rapid diagnosis of IDH1-mutated gliomas by 2-HG detection with gas chromatography mass spectrometry. | 2019 Apr |
2 |
| 33 |
30575118 | The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas. | 2019 May |
1 |
| 34 |
30857299 | Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins. | 2019 Mar 9 |
1 |
| 35 |
30862724 | Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. | 2019 Jun |
1 |
| 36 |
31086759 | Baseballs, tennis balls, livestock farm manure, the IDH1 mutation, endothelial cell proliferation and hypoxic pseudopalisading (granulomatous) necrosis: Mycobacterium avium subspecies paratuberculosis and the epidemiology, cellular metabolism and histology of diffuse gliomas, including glioblastoma. | 2019 Apr |
3 |
| 37 |
31105869 | Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production. | 2019 Apr 12 |
3 |
| 38 |
31139406 | Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate. | 2019 |
4 |
| 39 |
31155409 | Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. | 2019 Jul |
1 |
| 40 |
31221981 | The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. | 2019 Jun 20 |
1 |
| 41 |
31257503 | IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1‑mutant tumor cells. | 2019 Aug |
3 |
| 42 |
31475115 | IDH1 as a Cooperating Mutation in AML Arising in the Context of Shwachman-Diamond Syndrome. | 2019 |
2 |
| 43 |
29382206 | TOF-SIMS analysis of an isocitrate dehydrogenase 1 mutation-associated oncometabolite in cancer cells. | 2018 Jan 30 |
2 |
| 44 |
29439493 | Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies. | 2018 Feb 11 |
2 |
| 45 |
29458964 | Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates. | 2018 Feb |
1 |
| 46 |
29545476 | D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced MIR148A Promoter Methylation. | 2018 Jun |
2 |
| 47 |
29547090 | Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma. | 2018 Mar 16 |
1 |
| 48 |
29723602 | Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations. | 2018 Aug |
1 |
| 49 |
29733964 | Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation. | 2018 Aug 10 |
2 |
| 50 |
29773061 | Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer. | 2018 |
1 |